Trials / Completed
CompletedNCT02732951
Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema
A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Pharmacodynamics, Safety and Tolerability of Orally Administered BI 1026706 for 12 Weeks in Patients With Mild Visual Impairment Due to Center-involved Diabetic Macular Edema (DME)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a proof of mechanism trial to explore the effect of BI 1026706 on the central retinal thickness and to evaluate safety and tolerability of BI 1026706 administered orally for 12 weeks in patients with mild vision impairment due to center-involved DME
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1026706 | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-04-14
- Primary completion
- 2017-10-23
- Completion
- 2017-10-24
- First posted
- 2016-04-11
- Last updated
- 2019-03-20
- Results posted
- 2019-03-20
Locations
35 sites across 8 countries: Belgium, France, Germany, Greece, Hungary, Portugal, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02732951. Inclusion in this directory is not an endorsement.